Table 1.
Pilot study: demographic table and clinical data in schizophrenia and controls.
| Case # | Age (years) | Race | gender | COD | PMI (hours) | pH | SZ subtype | APD type | TD |
|---|---|---|---|---|---|---|---|---|---|
| SCHIZOPHRENIA (N = 6) | |||||||||
| SZ1 | 53 | C | M | ASCVD | 14 | 6.01 | Undifferentiated | Quetiapine (A) | Yes |
| SZ2 | 48 | AA | M | Narcotic intoxication | 24 | 7.07 | NOS | Quetiapine (A) | un |
| SZ3 | 83 | C | M | Electrocution | 18 | 6.98 | NOS | Quetiapine (A) | un |
| SZ4 | 46 | C | F | DVT | 25 | 6.18 | NOS | Clozapine (A) | un |
| SZ5 | 54 | C | M | Suicide (bleeding) | 19 | 6.58 | NOS | Quetiapine (A) | No |
| SZ6 | 42 | AA | F | ASCVD/MI | 13 | 5.86 | Chronic paranoid | Fluphenazine and Quetiapine (T + A) | Yes |
| Mean | 54.33 | 18.80 | 6.45 | ||||||
| SD | 14.73 | 4.96 | 0.51 | ||||||
| CONTROLS (N = 5) | |||||||||
| C1 | 49 | AA | F | Asthma | 19 | 6.19 | |||
| C2 | 51 | AA | M | ASCVD | 19 | 7.18 | |||
| C3 | 45 | C | F | Cardiac arrhythmia | 16 | 6.69 | |||
| C4 | 62 | C | M | Cardiac arrest | 19 | 6.48 | |||
| C5 | 67 | AA | M | ASCVD | 17 | 6.68 | |||
| Mean | 54.80 | 18.0 | 6.64 | ||||||
| SD | 9.28 | 1.41 | 0.36 | ||||||
A, atypical antipsychotic; AA, African American; APD, antipsychotic drug; ASCVD, arteriosclerotic cardiovascular disease; C, Caucasian; COD, cause of death; DVT, deep vein thrombosis; F, female; M, male; MI, myocardial infarction; NOS, not otherwise specified; PMI, postmortem interval; SD, standard deviation; SZ subtype, schizophrenia subtype; T, typical antipsychotic; TD, tardive dyskinesia; un, unknown.